Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus AMINOSYN II 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus AMINOSYN II 7.
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSYN II 7%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and nitrogen balance; dextrose provides caloric energy for metabolic processes; electrolytes maintain fluid and electrolyte homeostasis.
Aminosyn II 7% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It acts as a substrate for protein synthesis and supports metabolic functions in patients unable to tolerate oral or enteral nutrition.
Intravenous infusion: 500 mL to 2 L per day, administered via central line at a rate not exceeding 1 mL/min for initial 30 minutes, then increase to 2 mL/min if tolerated. Dose based on patient's protein and energy requirements; typical protein equivalent: 4.25 g/100 mL.
Intravenous infusion; typical adult dose: 0.8-1.5 g amino acids/kg/day (11.4-21.4 mL/kg/day of 7% solution); rate not exceeding 0.1 g amino acids/kg/hour.
None Documented
None Documented
Amino acids: variable, ~10-30 min for most; dextrose: ~1-2 h terminal half-life in healthy adults, prolonged in renal impairment.
Not applicable; exogenous amino acids are rapidly cleared from plasma with a terminal half-life of 15-20 minutes for individual amino acids.
Renal excretion of amino acids and dextrose metabolites; >90% of infused amino nitrogen is excreted renally as urea, with minimal biliary/fecal elimination.
Renal as amino acids and metabolites; negligible biliary/fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution